Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Other Operating Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other Operating Expenses for 10 consecutive years, with -$1000.0 as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses changed N/A to -$1000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1000.0 through Dec 2025, down 100.02% year-over-year, with the annual reading at $4.5 million for FY2024, N/A changed from the prior year.
  • Other Operating Expenses for Q4 2025 was -$1000.0 at Theravance Biopharma, down from $1.6 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $3.8 million in Q2 2022, with the low at -$37.5 million in Q3 2022.
  • Average Other Operating Expenses over 4 years is -$4.6 million, with a median of $42000.0 recorded in 2021.
  • The sharpest move saw Other Operating Expenses tumbled 67.69% in 2021, then crashed 188.1% in 2022.
  • Over 4 years, Other Operating Expenses stood at $42000.0 in 2021, then plummeted by 188.1% to -$37000.0 in 2022, then surged by 4321.62% to $1.6 million in 2024, then plummeted by 100.06% to -$1000.0 in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at -$1000.0, $1.6 million, and $3.0 million for Q4 2025, Q3 2024, and Q2 2024 respectively.